Japanese startup Iwaya Giken is launching a space tourism business to take sightseers on balloon rides 25 kilometers into the stratosphere
Iwaya Giken noted that while passengers need not undergo special training to make the trip but ticket prices would not be cheap, initially starting at around 24 million yen ($178,100) per person.
Company President Keisuke Iwaya said they will be able to reduce the price to the 1 million yen to 2 million yen range in the future.
Iwaya Giken may begin offering the service by the end of the year.
The service lets passengers ride on the balloon that would ascend for two hours, and stay in the stratosphere for an hour, letting them enjoy the view.
The cabin of the 41-meter-high balloon, which seats two people, is spherical and has a 1.5-meter diameter.
The balloon measures 41 meters high and has a spherical two-seater cabin, which is 1.5 meters in diameter.
The cabin was designed to be impervious to variations in air pressure and temperature. In the event of an emergency, it may be converted into a parachute and outfitted with life support systems.
Iwaya claimed that it created everything in-house to ensure safety, including its communication devices.
By the end of this year, the company hopes to hire five passengers and a pilot for the initial batch of flights, which it hopes to begin from Hokkaido.
It has conducted more than 300 flight tests, with the highest point reaching about 40 kilometers into the sky.
The firm is partnering with a major travel agency, JTB Corp., to organize the tours.
After analyzing the results of the experiments and test flights, JTB Corp. will determine whether it is ready to start selling package deals.


Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Neuralink Expands Brain Implant Trials with 12 Global Patients
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Parents abused by their children often suffer in silence – specialist therapy is helping them find a voice
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
6 simple questions to tell if a ‘finfluencer’ is more flash than cash
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Australia’s December Trade Surplus Expands but Falls Short of Expectations
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Why have so few atrocities ever been recognised as genocide?
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 



